Example: confidence
Discontinuation of Phyllocontin® (aminophylline) 225mg …
Memo re discontinuation of Phyllocontin® (aminophylline) 225mg and 350mg modified release tablets Page . 2. of . 3. Switching medications . The following advice should be used to support switching to Uniphyllin Continus® (oral theophylline tablets) in patients for whom treatment with a methylxanthine is still required
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Direct Oral Anticoagulant (DOAC) Interactions
www.ncl-mon.nhs.ukintended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are only, their interpretation and application remain the for guidance responsibility of the individual clinician. If in doubt, contact a senior colleague or …
Factsheet Lithium Preparations
www.ncl-mon.nhs.ukthyroxine. Monitor thyroid function tests. Polyuria and polydipsia *Uncommon Transient following initiation. Try reducing dose. May occur more frequently with twice-daily dosing. If persists, check creatinine and U&Es. Advise patient drinks fluid in moderation to avoid changes in fluid balance. Diarrhoea *Uncommon May be a sign of toxicity ...
Guidance for the management of hypertriglyceridaemia
www.ncl-mon.nhs.ukof cardiovascular disease1 (full lifestyle advice published in NICE CG1812) Cardioprotective diet including: o Restrict consumption of high glycaemic index/load foods as well as refined sugars, fruit juices, and high fructose beverages 1 o Increased consumption of oily fish 1,2 (pregnant women to limit their oily fish to no more
NCL Guideline for the treatment of Chronic Spontaneous ...
www.ncl-mon.nhs.ukUrticaria is a superficial swelling of the skin (epidermis and mucous membranes) that results in red, raised, itchy wheals.1 Theories regarding the pathogenesis of urticaria include mast-cell-derived pro-inflammatory mediators (such as histamine), which is amongst one of the best developed hypotheses.2 Chronic Spontaneous Urticaria is defined ...
Factsheet - Antipsychotic Monitoring
www.ncl-mon.nhs.ukPLEASE NOTE THIS IS NOT A SHARED CARE GUIDELINE, NOR IS IT A FULL SUMMARY OF DRUG INFORMATION. ... abnormal lipid levels or problems with blood glucose management, consider a referral to a specialist. 1. ... Management of high glucose should be in line with NICE guidance “type 2 diabetes in adults: management.”
Direct Oral Anticoagulant (DOAC) counselling checklist
www.ncl-mon.nhs.uk15. Surgical procedures (including dental treatment) and hospital admission: patient must inform healthcare professional that s/he is taking DOAC especially as: patient will need management of anticoagulation around procedures and VTE thromboprophylaxis (e.g. LMWH) is often prescribed on admission to hospital. 18.
Factsheet (Ozempic®), DULAGLUTIDE (Trulicity®) and ...
www.ncl-mon.nhs.ukNorth Central London Joint Formulary Committee 2 of 9 Semaglutide (Ozempic®), Dulaglutide and Liraglutide 1.2mg (Victoza®) Factsheet Approval date: Dec 2019 Version 1.2 Review Date: Aug 2022 ... (including sleep apnoea, non-alcoholic fatty liver disease [NAFLD], CKD secondary to obesity, musculoskeletal
Antihyperglycaemic agents for Type 2 diabetes
www.ncl-mon.nhs.ukDiet & Lifestyle first line therapy 1,2, 3 Provide Sick Day Guidance (page 7) Intensive diet & lifestyle management for all patients1. enrolment into NCL Low-Calorie Diet Programme for eligible patients, to support healthier lifestyle, weight loss, and remission of Type 2 diabetes. 2 ,3 5 + Gliclazide, or Basal insulin
Related documents
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - …
www.ema.europa.euconcomitant elevations were reversible with prompt discontinuation of tolvaptan, they represent a potential for significant liver injury. Similar changes with other medicinal products have been associated with the potential to cause irreversible and potentially life …
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - Europa
www.ema.europa.euManagement of some adverse reactions may require dose interruption, adjustment, or discontinuation of lenvatinib therapy. Mild to moderate adverse reactions (e.g., Grade 1 or 2) generally do not warrant interruption of lenvatinib, unless intolerable to the patient despite optimal management. For lenvatinib-related toxicities, see Table 4.
Product Discontinuation Notice for Intel® WiDi and Intel ...
downloadmirror.intel.comProduct Discontinuation Notice for Intel® WiDi and Intel® Pro WiDi Intel has discontinued marketing and development for Intel® Wireless Display (Intel® WiDi) and Intel® Pro Wireless Display (Intel® Pro WiDi) applications and related …
Product Discontinuation Notice - Hikvision
www.hikvision.comproduct line. iVMS-4200 Client Software covers all the functions of iVMS-4200 VS Client Software. Therefore, in order to improve the efficiency and provide better service to our customers, HIKVISION will discontinue iVMS-4200 VS Client Software from January 31, 2021. Discontinued Product Information: Series Name Date of Discontinuation
PRODUCT MONOGRAPH
pdf.hres.caPRODUCT MONOGRAPH Pr WELLBUTRIN ... aware that symptoms may persist beyond the discontinuation of bupropion, and clinical management should be provided accordingly. In post-market experience, there have been reports of hypersensitivity reactions in